Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Washington
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
University of Virginia
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
University of California, Irvine
University of California, Irvine
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Fred Hutchinson Cancer Center
Imagine Institute
City of Hope Medical Center
University Health Network, Toronto
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Alabama at Birmingham
University of Washington
Montefiore Medical Center
Azienda Ospedaliero-Universitaria di Parma
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
Wake Forest University Health Sciences
Mayo Clinic
Mayo Clinic
Children's Hospital of Philadelphia
University of Miami
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Children's Hospital Medical Center, Cincinnati
M.D. Anderson Cancer Center
Azienda Ospedaliero-Universitaria di Parma
Immune Oncology Research Institute
Azienda Ospedaliero-Universitaria di Parma
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Alliance for Clinical Trials in Oncology
University of Southern California
Stanford University
Fred Hutchinson Cancer Center
MPN Research Foundation